Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates to use as molecular biomarkers in clinical practice. However, lncRNA studies in breast cancer are limited in sample size and are restricted to the determination of their biological function, which represents an obstacle for its inclusion as molecular biomarkers of clinical utility. Nevertheless, due to their expression specificity among diseases, such as cancer, and their stability in body fluids, lncRNAs are promising molecular biomarkers that could improve the reliability, sensitivity, and specificity of molecular techniques used in clinical diagnosis. The development of lncRNA-based diagnostics and lncRNA-based therapeutics will be useful in routine medical practice to improve patient clinical management and quality of life.
SARS-CoV-2 is a coronavirus family member that appeared in China in December 2019 and caused the disease called COVID-19, which was declared a pandemic in 2020 by the World Health Organization. In recent months, great efforts have been made in the field of basic and clinical research to understand the biology and infection processes of SARS-CoV-2. In particular, transcriptome analysis has contributed to generating new knowledge of the viral sequences and intracellular signaling pathways that regulate the infection and pathogenesis of SARS-CoV-2, generating new information about its biology. Furthermore, transcriptomics approaches including spatial transcriptomics, single-cell transcriptomics and direct RNA sequencing have been used for clinical applications in monitoring, detection, diagnosis, and treatment to generate new clinical predictive models for SARS-CoV-2. Consequently, RNA-based therapeutics and their relationship with SARS-CoV-2 have emerged as promising strategies to battle the SARS-CoV-2 pandemic with the assistance of novel approaches such as CRISPR-CAS, ASOs, and siRNA systems. Lastly, we discuss the importance of precision public health in the management of patients infected with SARS-CoV-2 and establish that the fusion of transcriptomics, RNA-based therapeutics, and precision public health will allow a linkage for developing health systems that facilitate the acquisition of relevant clinical strategies for rapid decision making to assist in the management and treatment of the SARS-CoV-2-infected population to combat this global public health problem.
LncRNAs are noncoding transcripts with tissue and cancer specificity. Particularly, in breast cancer, lncRNAs exhibit subtype-specific expression; they are particularly upregulated in luminal tumors. However, no gene signature-based laboratory tests have been developed for luminal breast cancer identification or the differential diagnosis of luminal tumors, since no luminal A- or B-specific genes have been identified. Particularly, luminal B patients are of clinical interest, since they have the most variable response to neoadjuvant treatment; thus, it is necessary to develop diagnostic and predictive biomarkers for these patients to optimize treatment decision-making and improve treatment quality. In this study, we analyzed the lncRNA expression profiles of breast cancer cell lines and patient tumor samples from RNA-Seq data to identify an lncRNA signature specific for luminal phenotypes. We identified an lncRNA signature consisting of LINC01016, GATA3-AS1, MAPT-IT1, and DSCAM-AS1 that exhibits luminal subtype-specific expression; among these lncRNAs, GATA3-AS1 is associated with the presence of residual disease (Wilcoxon test, p < 0.05), which is related to neoadjuvant chemotherapy resistance in luminal B breast cancer patients. Furthermore, analysis of GATA3-AS1 expression using RNA in situ hybridization (RNA ISH) demonstrated that this lncRNA is detectable in histological slides. Similar to estrogen receptors and Ki67, both commonly detected biomarkers, GATA3-AS1 proves to be a suitable predictive biomarker for clinical application in breast cancer laboratory tests.
Malnutrition and systemic inflammation significantly worsen the prognosis of oncology patients, contributing to 10–20% of cancer-related deaths. While the Carcinoembryonic Antigen (CEA) reflects tumor burden, the Prognostic Nutritional Index (PNI) captures nutritional and immune status. This study aimed to evaluate whether the combination of CEA and PNI provides superior prognostic stratification compared to either biomarker alone in patients with metastatic colorectal cancer (mCRC). This retrospective cohort study analyzed data from 512 mCRC patients at baseline and at the first response assessment (after two months of systemic treatment). Patients were stratified into four groups based on CEA (<5 or ≥5 ng/mL) and PNI (<37.52 or ≥37.52). Overall Survival (OS) and Progression-Free Survival (PFS) were analyzed using the Kaplan-Meier method and Cox regression. Our results showed that the prevalence of PNI LOW was 49.8% at diagnosis and increased to 54.4% after chemotherapy (p = 0.047). PNI and Body Mass Index (BMI) status alone were not significant predictors of OS or PFS. In contrast, CEA was a powerful indicator, with CEA HIGH consistently predicting worse OS and PFS. Crucially, the combined CEA/PNI score provided the strongest discrimination. Patients with the high-risk profile (CEA HIGH /PNI LOW ) had a significantly increased risk of death (HR 2.41, p = 0.01) and progression (HR 2.30, p < 0.01) at baseline, compared to the lowest-risk group (CEA LOW /PNI HIGH ). This elevated risk was maintained at the first assessment (HR 2.30, p < 0.01 for death and HR 6.81, p < 0.01 for progression). We conclude that PNI alone is insufficient to predict survival in mCRC patients. However, its integration with CEA creates a robust, easily obtainable biomarker that provides superior prognostic stratification by combining information on tumor burden and host systemic status.